Literature DB >> 30697727

CRISPR/Cas9 technology as a potent molecular tool for gene therapy.

Ansar Karimian1,2,3, Khalil Azizian4, Hadi Parsian1, Sona Rafieian5, Vahid Shafiei-Irannejad6, Maryam Kheyrollah7, Mehdi Yousefi8,9, Maryam Majidinia10, Bahman Yousefi11,12.   

Abstract

Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRISPR-Cas9) is an RNA-guided gene editing tool which offers several advantageous characteristics in comparison with the conventional methods (e.g., zinc finger nucleases and transcription activator-like effector nucleases) such as cost-effectiveness, flexibility, and being easy-to-use. Despite some limitations such as efficient delivery and safety, CRISPR-Cas9 is still the most convenient tool for gene editing purposes. Due to the potential capability of the CRISPR-Cas9 system in genome editing and correction of casual mutations, it can be considered as a possible therapeutic system in the treatment of disorders associated with the genome mutations and in particular cancer treatment. In this review, we will discuss CRISPR-Cas-based gene editing along with its classifications and mechanism of action. Furthermore, the therapeutic application of the CRISPR-Cas9 system in mutational disorders, delivery systems, as well as its advantages and limitations with a special emphasis on cancer treatment will be discussed.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRISPR-Cas9; cancer treatment; gene therapy; genome editing

Mesh:

Year:  2019        PMID: 30697727     DOI: 10.1002/jcp.27972

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  27 in total

1.  Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA.

Authors:  Andrés Felipe Leal; Carlos Javier Alméciga-Díaz
Journal:  Gene Ther       Date:  2022-05-18       Impact factor: 5.250

Review 2.  Advances in gene therapy for neurogenetic diseases: a brief review.

Authors:  Ying-Xuan Xie; Wen-Qi Lv; Yi-Kun Chen; Shunyan Hong; Xiang-Ping Yao; Wan-Jin Chen; Miao Zhao
Journal:  J Mol Med (Berl)       Date:  2021-11-27       Impact factor: 4.599

3.  A Brief Introduction to Current Cancer Gene Therapy.

Authors:  Dennis Kobelt; Jessica Pahle; Wolfgang Walther
Journal:  Methods Mol Biol       Date:  2022

4.  Construction of TSC2 knockout cell line using CRISPR/Cas9 system and demonstration of its effects on NIH-3T3 cells.

Authors:  Xu Wang; Yang Zhao; Zhan Wang; Zhangcheng Liao; Yushi Zhang
Journal:  Cell Biochem Biophys       Date:  2022-10-01       Impact factor: 2.989

Review 5.  Ten decadal advances in fungal biology leading towards human well-being.

Authors:  Ausana Mapook; Kevin D Hyde; Khadija Hassan; Blondelle Matio Kemkuignou; Adéla Čmoková; Frank Surup; Eric Kuhnert; Pathompong Paomephan; Tian Cheng; Sybren de Hoog; Yinggai Song; Ruvishika S Jayawardena; Abdullah M S Al-Hatmi; Tokameh Mahmoudi; Nadia Ponts; Lena Studt-Reinhold; Florence Richard-Forget; K W Thilini Chethana; Dulanjalee L Harishchandra; Peter E Mortimer; Huili Li; Saisamorm Lumyong; Worawoot Aiduang; Jaturong Kumla; Nakarin Suwannarach; Chitrabhanu S Bhunjun; Feng-Ming Yu; Qi Zhao; Doug Schaefer; Marc Stadler
Journal:  Fungal Divers       Date:  2022-09-15       Impact factor: 24.902

6.  LRP6-CRISPR prevents activation of hepatic stellate cells and liver fibrogenesis in rats.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

Review 7.  Advances in genome editing for genetic hearing loss.

Authors:  Ning Ding; Sangsin Lee; Matan Lieber-Kotz; Jie Yang; Xue Gao
Journal:  Adv Drug Deliv Rev       Date:  2020-05-07       Impact factor: 15.470

8.  Australia and New Zealand renal gene panel testing in routine clinical practice of 542 families.

Authors:  Hope A Tanudisastro; Katherine Holman; Gladys Ho; Elizabeth Farnsworth; Katrina Fisk; Thet Gayagay; Emma Hackett; Gemma Jenkins; Rahul Krishnaraj; Tiffany Lai; Karen Wong; Chirag Patel; Amali Mallawaarachchi; Andrew J Mallett; Bruce Bennetts; Stephen I Alexander; Hugh J McCarthy
Journal:  NPJ Genom Med       Date:  2021-03-04       Impact factor: 8.617

Review 9.  Small nucleic acids and the path to the clinic for anti-CRISPR.

Authors:  Christopher L Barkau; Daniel O'Reilly; Seth B Eddington; Masad J Damha; Keith T Gagnon
Journal:  Biochem Pharmacol       Date:  2021-02-27       Impact factor: 6.100

Review 10.  Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.

Authors:  Dito Anurogo; Nova Yuli Prasetyo Budi; Mai-Huong Thi Ngo; Yen-Hua Huang; Jeanne Adiwinata Pawitan
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.